CABAZITAXEL

Cabazitaxel Adverse Events Reported to the FDA Over Time

How are Cabazitaxel adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Cabazitaxel, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Cabazitaxel is flagged as the suspect drug causing the adverse event.

Most Common Cabazitaxel Adverse Events Reported to the FDA

What are the most common Cabazitaxel adverse events reported to the FDA?

Pulmonary Embolism	51 (5.01%)
Sepsis	29 (2.85%)
Neutropenia	26 (2.56%)
Death	25 (2.46%)
Diarrhoea	25 (2.46%)
Pancytopenia	24 (2.36%)
Pneumonia	20 (1.97%)
Syncope	20 (1.97%)
Anaemia	19 (1.87%)
Thrombocytopenia	19 (1.87%)
Cholecystitis	18 (1.77%)
	Show More
Gastrointestinal Haemorrhage	17 (1.67%)
Duodenal Ulcer	16 (1.57%)
Gastritis	14 (1.38%)
Hypocalcaemia	14 (1.38%)
Pyrexia	14 (1.38%)
Cardio-respiratory Arrest	13 (1.28%)
Disseminated Intravascular Coagulat...	13 (1.28%)
Hypotension	13 (1.28%)
Deep Vein Thrombosis	12 (1.18%)
Dehydration	12 (1.18%)
Febrile Neutropenia	11 (1.08%)
Cardiac Failure	10 (.98%)
Cystitis Radiation	10 (.98%)
Fall	10 (.98%)
Haematuria	10 (.98%)
Nausea	10 (.98%)
Neutropenic Sepsis	10 (.98%)
Pneumonitis	10 (.98%)
Renal Failure Acute	10 (.98%)
Sudden Death	10 (.98%)
Asthenia	9 (.88%)
Cerebral Haemorrhage	9 (.88%)
Haemorrhagic Anaemia	9 (.88%)
Leukopenia	9 (.88%)
Septic Shock	9 (.88%)
Agranulocytosis	8 (.79%)
Colitis	8 (.79%)
Diabetes Mellitus	8 (.79%)
Small Intestinal Haemorrhage	8 (.79%)
Cardiac Failure Congestive	7 (.69%)
Disease Progression	7 (.69%)
Multi-organ Failure	7 (.69%)
Neoplasm Progression	7 (.69%)
Pulmonary Oedema	7 (.69%)
Urinary Tract Infection	7 (.69%)
Vomiting	7 (.69%)
Acute Coronary Syndrome	6 (.59%)
Atrial Fibrillation	6 (.59%)
Back Pain	6 (.59%)
Cachexia	6 (.59%)
Chemical Cystitis	6 (.59%)
Diverticulum Intestinal Haemorrhagi...	6 (.59%)
Febrile Bone Marrow Aplasia	6 (.59%)
Gastric Ulcer	6 (.59%)
Hypoglycaemia	6 (.59%)
Myocardial Infarction	6 (.59%)
Pain In Extremity	6 (.59%)
Phlebitis Infective	6 (.59%)
Respiratory Failure	6 (.59%)
Small Intestinal Obstruction	6 (.59%)
Acute Myocardial Infarction	5 (.49%)
Duodenal Ulcer Haemorrhage	5 (.49%)
General Physical Health Deteriorati...	5 (.49%)
Abdominal Pain	4 (.39%)
Accidental Overdose	4 (.39%)
Acute Respiratory Failure	4 (.39%)
Aortic Dissection	4 (.39%)
Cataract	4 (.39%)
Circulatory Collapse	4 (.39%)
Confusional State	4 (.39%)
Diabetic Ketoacidosis	4 (.39%)
Duodenal Perforation	4 (.39%)
Embolism	4 (.39%)
Erysipelas	4 (.39%)
Gastric Ulcer Haemorrhage	4 (.39%)
Generalised Oedema	4 (.39%)
Haematochezia	4 (.39%)
Haemoptysis	4 (.39%)
Hydronephrosis	4 (.39%)
Hyperglycaemia	4 (.39%)
Implant Site Reaction	4 (.39%)
Large Intestinal Haemorrhage	4 (.39%)
Neutropenic Infection	4 (.39%)
Oedema	4 (.39%)
Paraparesis	4 (.39%)
Pleurisy	4 (.39%)
Spinal Cord Compression	4 (.39%)
Transaminases Increased	4 (.39%)
Weight Increased	4 (.39%)
Blood Creatinine Increased	3 (.29%)
Ejection Fraction Decreased	3 (.29%)
Hyponatraemia	3 (.29%)
Ileus Paralytic	3 (.29%)
Jaundice	3 (.29%)
Metastases To Central Nervous Syste...	3 (.29%)
Renal Failure	3 (.29%)
Rhabdomyolysis	3 (.29%)
Shock	3 (.29%)
Abdominal Distension	2 (.2%)
Arrhythmia	2 (.2%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Cabazitaxel, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Cabazitaxel is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Cabazitaxel

What are the most common Cabazitaxel adverse events reported to the FDA?

Infections - Pathogen Unspecified	90 (8.85%)
Anemias Nonhemolytic And Marrow Dep...	60 (5.9%)
White Blood Cell	54 (5.31%)
Pulmonary Vascular	53 (5.21%)
Gastrointestinal Hemorrhages	39 (3.83%)
Gastrointestinal Ulceration And Per...	36 (3.54%)
Fatal Outcomes	35 (3.44%)
Neurological	31 (3.05%)
Gastrointestinal Motility And Defec...	29 (2.85%)
Gastrointestinal Inflammatory Condi...	28 (2.75%)
Gastrointestinal Signs	25 (2.46%)
	Show More
Cardiac Arrhythmias	24 (2.36%)
Decreased And Nonspecific Blood Pre...	21 (2.06%)
Gallbladder	20 (1.97%)
Heart Failures	19 (1.87%)
Lower Respiratory Tract Disorders	19 (1.87%)
Platelet	19 (1.87%)
Coronary Artery	18 (1.77%)
Glucose Metabolism Disorders	18 (1.77%)
Respiratory	18 (1.77%)
Electrolyte And Fluid Balance Condi...	17 (1.67%)
Renal Disorders	17 (1.67%)
Embolism And Thrombosis	16 (1.57%)
Body Temperature Conditions	14 (1.38%)
Bone, Calcium, Magnesium And Phosph...	14 (1.38%)
Coagulopathies And Bleeding Diathes...	13 (1.28%)
Musculoskeletal And Connective Tiss...	13 (1.28%)
Urinary Tract Signs	13 (1.28%)
Central Nervous System Vascular	12 (1.18%)
Injuries	10 (.98%)
Injuries By Physical Agents	10 (.98%)
Miscellaneous And Site Unspecified ...	9 (.88%)
Appetite And General Nutritional	8 (.79%)
Muscle	7 (.69%)
Cardiac And Vascular Investigations	6 (.59%)
Chemical Injury And Poisoning	6 (.59%)
Diverticular	6 (.59%)
Gastrointestinal Stenosis And Obstr...	6 (.59%)
Hematology Investigations	6 (.59%)
Administration Site Reactions	5 (.49%)
Hepatic And Hepatobiliary	5 (.49%)
Medication Errors	5 (.49%)
Pleural	5 (.49%)
Vascular	5 (.49%)
Aneurysms And Artery Dissections	4 (.39%)
Anterior Eye Structural Change, Dep...	4 (.39%)
Bacterial Infectious	4 (.39%)
Bronchial Disorders	4 (.39%)
Cardiac Valve	4 (.39%)
Deliria	4 (.39%)
Diabetic Complications	4 (.39%)
Hepatobiliary	4 (.39%)
Movement Disorders	4 (.39%)
Peripheral Neuropathies	4 (.39%)
Physical Examination Topics	4 (.39%)
Renal And Urinary Tract Investigati...	4 (.39%)
Spinal Cord And Nerve Root	4 (.39%)
Enzyme	3 (.29%)
Epidermal And Dermal Conditions	3 (.29%)
Metastases	3 (.29%)
Cardiac Disorder Signs	2 (.2%)
Gastrointestinal Vascular Condition...	2 (.2%)
Hemolyses And Related Conditions	2 (.2%)
Hepatobiliary Neoplasms Malignant A...	2 (.2%)
Procedural And Device Related Injur...	2 (.2%)
Protein And Amino Acid Metabolism	2 (.2%)
Reproductive Tract	2 (.2%)
Respiratory And Mediastinal Neoplas...	2 (.2%)
Skin Appendage Conditions	2 (.2%)
Upper Respiratory Tract Disorders	2 (.2%)
Venous Varices	2 (.2%)
Bone Disorders	1 (.1%)
Fractures	1 (.1%)
Gastrointestinal Neoplasms Malignan...	1 (.1%)
Hearing	1 (.1%)
Joint	1 (.1%)
Peritoneal And Retroperitoneal Cond...	1 (.1%)
Therapeutic And Nontherapeutic Effe...	1 (.1%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Cabazitaxel, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Cabazitaxel is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.